Improvements in quality of life and work productivity make omalizumab cost-effective for the treatment of chronic spontaneous urticaria

被引：0
|
作者：
Goncalo, M. [1 ,2 ]
机构：
[1] Univ Coimbra, Univ Hosp, Clin Dermatol, Coimbra, Portugal
[2] Univ Coimbra, Fac Med, Coimbra, Portugal
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2018年 / 179卷 / 03期
关键词：
D O I：
10.1111/bjd.16820
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：562 / 563
页数：2
相关论文
共 50 条
  • [41] Combined use of ciclosporin and omalizumab for the treatment of chronic spontaneous urticaria
    Smith, Helin
    Denman, Sarah
    Ford, Kate
    Toolan, John
    Savic, Sinisa
    CLINICAL AND EXPERIMENTAL ALLERGY, 2019, 49 (12): : 1665 - 1665
  • [42] Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria
    Finlay, A. Y.
    Kaplan, A. P.
    Beck, L. A.
    Antonova, E. N.
    Balp, M-M
    Zazzali, J.
    Khalil, S.
    Maurer, M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (10) : 1715 - 1721
  • [43] COST-UTILITY OF OMALIZUMAB COMPARED WITH STANDARD OF CARE FOR THE TREATMENT OF CHRONIC SPONTANEOUS URTICARIA (CSU)
    Graham, J.
    McBride, D.
    Stull, D.
    Halliday, A.
    Alexopoulos, S. T.
    Balp, M.
    Griffiths, M.
    Agirrezabal, I
    Brennan, A.
    VALUE IN HEALTH, 2015, 18 (07) : A423 - A423
  • [44] ECONOMIC AND HUMANISTIC BURDEN OF CHRONIC SPONTANEOUS URTICARIA IN BRAZIL: IMPACT ON WORK PRODUCTIVITY, RESOURCE UTILIZATION AND QUALITY OF LIFE
    Balp, M.
    Lopes, N.
    Tian, H.
    Vietri, J.
    Ensina, L. F.
    VALUE IN HEALTH, 2016, 19 (07) : A617 - A617
  • [45] Efficacy of Omalizumab in Treatment-Resistant Chronic Spontaneous Urticaria
    Tabanlioglu-Onan, Duru
    Oktem, Ayse
    Yalcin, Basak
    Artuz, Ferda
    ASTIM ALLERJI IMMUNOLOJI, 2019, 17 (01): : 41 - 46
  • [46] Omalizumab treatment for chronic spontaneous urticaria: data from Turkey
    Kara, Rabia Oztas
    Dikicier, Bahar Sevimli
    Yaldiz, Mahizer
    Koku, Busra
    Cosansu, Nur Cihan
    Solak, Berna
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2022, 39 (04): : 704 - 707
  • [47] Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria: a critical appraisal
    Durack, A.
    Matin, R. N.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 (01) : 10 - 13
  • [48] Omalizumab treatment in adolescents with chronic spontaneous urticaria: Efficacy and safety
    Kahveci, M.
    Soyer, O.
    Buyuktiryaki, B.
    Sekerel, B. E.
    Sahiner, U. M.
    ALLERGOLOGIA ET IMMUNOPATHOLOGIA, 2020, 48 (04) : 368 - 373
  • [49] Omalizumab treatment in children with chronic spontaneous urticaria: Efficacy and safety
    Kahveci, M.
    Sahiner, U. M.
    Buyuktiryaki, B.
    Sekerel, B. E.
    Soyer, O.
    ALLERGY, 2019, 74 : 867 - 868
  • [50] Treatment response to omalizumab in patients with refractory chronic spontaneous urticaria
    Syrigos, Nikolaos
    Grapsa, Dimitra
    Zande, Maria
    Tziotou, Marianna
    Syrigou, Ekaterini
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2018, 57 (04) : 417 - 422
12345